OS Therapies (NYSE:OSTX) Receives “Buy” Rating from D. Boral Capital

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $20.00 price target on the stock.

Separately, Lake Street Capital started coverage on shares of OS Therapies in a research report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 price objective on the stock. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $18.00.

OS Therapies Price Performance

NYSE OSTX opened at $1.70 on Tuesday. OS Therapies has a 12 month low of $1.12 and a 12 month high of $7.00. The company has a market capitalization of $47.77 million and a price-to-earnings ratio of -1.98. The firm’s fifty day moving average price is $1.74 and its 200 day moving average price is $2.27.

Insider Buying and Selling

In related news, major shareholder Shalom Auerbach sold 82,000 shares of the business’s stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $2.00, for a total value of $164,000.00. Following the sale, the insider now directly owns 2,664,199 shares in the company, valued at $5,328,398. The trade was a 2.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 13.80% of the company’s stock.

Institutional Trading of OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC raised its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,044 shares of the company’s stock after buying an additional 60,044 shares during the period. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.